<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

Virtual US Symposium

Clinically-Relevant Tumor Models for Cancer Drug Discovery and Development

December 9th 2020 - 9am PST

Virtual US SymposiumJoin our Virtual US Symposium to learn more about using advanced, clinically-relevant models to accelerate oncology drug development.

Clinical relevance is essential in preclinical oncology and I/O studies to ensure translatability of results, and the greatest chance of downstream agent success. With rapid innovation across patient-derived, humanized, and models recapitulating other clinical features needed for immunotherapy studies, the next generation of anticancer agents can be designed, assessed, and progressed through the drug development pipeline in a more efficient manner.

Attend this Symposium to Explore:

  • The role of modeling clinical resistance in the development of new anticancer agents
  • How new, translational platforms such as tumor organoids are used to evaluate CAR-T cell therapies
  • The latest breakthroughs in humanized mouse models

Who Should Attend?

Oncology and immuno-oncology R&D and preclinical teams from pharmaceutical and biotech companies looking to facilitate cross discipline discussions on current drug discovery and development models and techniques, and how to move forward with future approaches.


Dr Sylvia Boj

Chief Scientific Officer, Hubrecht Organoid Technology (HUB)
HUB Organoids: Patient in the Lab

Dr Anthony Tolcher

CEO, Founder, and Director of Clinical Research, NEXT Oncology
Why Models That Reflect Patients Resistant to New Therapies Are Key To Breakthroughs

Dr Gerold Feuer

Consultant, Feuer Consulting Services
Modeling Human Tumor Engraftment and Treatments in Humanized Mice: A HuMurine Technologies Perspective

Dr Fiore Cattaruzza

Director of Pharmacology and Preclinical Development, Amunix Pharmaceuticals
HER2-XPAT, A Novel Protease-Activatable Prodrug T Cell Engager (TCE), Engineered to Address On-Target, Off Tumor Toxicity and Provide Large Predicted Safety Margins in NHPs

Dr Dean Campbell

Director, Scientific Engagement, Crown Bioscience
Translational Preclinical Platforms for CAR-T Cell Therapy

Register Now!

Register Now

Your privacy is important to us.
We'll never share your information.